This article is more than 5 years old. Information may no longer be current.

Medacta receives FDA clearance, launches shoulder replacement device

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Medacta International announced clearance from the FDA for its Short Humeral Diaphysis, which is used with the Medacta Shoulder System.

According to the company’s press release, the Short Humeral Diaphysis is for primary and reverse shoulder replacement in patients with severe arthropathy or a grossly deficient rotator cuff. As an alternative to the Standard Humeral Diaphysis, the Short Humeral Diaphysis is an implantable device that replaces the humeral side of the gleno-humeral joint. Reducing device length minimizes the violation of the humeral intramedullary canal. The device is manufactured from titanium alloy and will be offered in 11 sizes.

“The addition of the Short Humeral Diaphysis to the Medacta Shoulder System means that surgeons will be able to achieve a more personalized fit for more patients, improving the patient and surgeon experience,” Francesco Siccardi, executive vice president of Medacta International said.

Medacta launched the Short Humeral Diaphysis at the San Diego Shoulder Institute's Annual Shoulder Course, held June 20-23 in San Diego.

Reference:

www.medacta.us.com